Who Owns 4D Molecular Therapeutics Stock?
NASDAQ: FDMTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 103.88%
- Institutions (% of float)
- 106.73%
- Held by insiders
- 2.67%
- Institutional holders
- 227
- Institutions 97.3%
- Insiders 2.7%
- Public and other 0.0%
Who owns 4D Molecular Therapeutics stock?
Institutional investors own about 103.9% of 4D Molecular Therapeutics's shares, spread across 227 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 2.67% of FDMT.
The largest institutional holders are Janus Henderson Group Ltd. (10.17%), RA Capital Management, L.P. (8.96%) and Blackrock Inc. (8.38%). Together, the top 10 institutions control 61.3% of shares outstanding. In their latest filings, 3 of the top 10 institutions increased their FDMT positions and 4 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of FDMT
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Janus Henderson Group Ltd. | 5.73M | 10.17% | +9.3% |
| RA Capital Management, L.P. | 5.05M | 8.96% | 0.0% |
| Blackrock Inc. | 4.72M | 8.38% | +3.9% |
| Goldman Sachs Group Inc | 3.93M | 6.97% | -7.7% |
| Novo Holdings A/S | 3.00M | 5.32% | -7.7% |
| BVF Inc. | 2.88M | 5.11% | 0.0% |
| State Street Corporation | 2.47M | 4.38% | -15.2% |
| Adage Capital Partners GP L.L.C. | 2.29M | 4.06% | +1.8% |
| T. Rowe Price Investment Management, Inc. | 2.27M | 4.02% | -9.8% |
| Trails Edge Capital Partners, LP | 2.23M | 3.95% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of FDMT
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.59M | 2.82% |
| iShares Trust-iShares Russell 2000 ETF | 1.19M | 2.10% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.17M | 2.08% |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 865.42K | 1.53% |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 681.92K | 1.21% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 501.54K | 0.89% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 460.48K | 0.82% |
| T. Rowe Price Small-Cap Value Fund, Inc. | 455.27K | 0.81% |
| iShares Trust-iShares Russell 2000 Value ETF | 428.65K | 0.76% |
| iShares Trust-iShares Biotechnology ETF | 390.90K | 0.69% |
Frequently asked questions
Who is the largest shareholder of 4D Molecular Therapeutics?
Janus Henderson Group Ltd. is the largest institutional shareholder of FDMT, owning 10.17% of shares outstanding (5.73M shares) as of its latest 13F filing.
What percentage of 4D Molecular Therapeutics is owned by institutions?
Institutions own about 103.9% of FDMT shares and 106.7% of the public float.
How much of 4D Molecular Therapeutics do insiders own?
Insiders, such as officers and directors, own about 2.67% of FDMT shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.